Oncotelic Therapeutics Business Summary

Oncotelic Therapeutics, Inc. (OTLC) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of strategic licensing, joint venture (JV) equity participation, and AI-driven service fees. The company’s operations are divided into three primary segments: Oncology/Virology, focused on its proprietary TGF-β antisense platform (OT-101) and vascular disrupting agents (OXi4503/CA4P); Central Nervous System (CNS), targeting Parkinson’s disease and sexual dysfunction via its AL-101 intranasal delivery system; and AI-Enabled Drug Discovery, which leverages its PDAOAI platform to provide evidence-interrogation services for third-party researchers. A significant portion of its current valuation is derived from its 45% stake in the GMP Bio joint venture, which manages a nanoparticle pipeline valued at approximately $1.7 billion. OTLC competes with major oncology players such as Eli Lilly, MedPacto, and Merck, positioning itself as a high-density niche specialist in rare pediatric cancers and TGF-β-centric immunotherapies. The leadership team is anchored by Co-Founder, Chairman, and CEO Dr. Vuong Trieu, a prolific biopharma pioneer credited with the invention and development of multi-billion-dollar assets including Abraxane and Cynviloq. Dr. Trieu is supported by a seasoned executive suite including CFO Amit Shah, Chief Clinical Officer Dr. Anthony E. Maida III, and CMO Dr. Seymour Fein, who collectively bring decades of experience in regulatory navigation and translational medicine. The company’s technological edge in artificial intelligence is directed by Saran Saund, CBO and GM of the AI Division, and Burcak Beser, CTO of the AI Division. Notable institutional backing and strategic partnership come from Dragon Capital Overseas Limited, which serves as the primary partner in the GMP Bio joint venture, providing critical manufacturing and financial infrastructure for Oncotelic’s late-stage clinical trials.